The Evaluation of the impact of reduction in the Protamine dose in comparison to its total dose after coronary artery bypass grafting
Phase 3
- Conditions
- Patients in need of coronary artery bypass grafting.
- Registration Number
- IRCT20220610055128N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Omitting anti-coagulation drugs at least one week prior to surgery
Patient should be a candidate for coronary artery bypass grafting
Informed consent to participate in the study
CPB duration less than 100 minutes
Exclusion Criteria
Allergy and the risk of anaphylaxia shock
Coagulation abnormality
Bleeding and hemostasis dysfunctions due to non-medical causes
Patients dependent on dialysis and patients suffering from blood dyscrasia and known platelet dysfunction
Pregnancy
Heparin re-administration
Need for emergency surgery
Patients with BMIs higher than 30
Under 28 degrees hypothermia
Dissent to participate in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent of participants with number of Activated Clotting Time near normal domain (70-120) second. Timepoint: 5 minutes after the end of protamine injection. Method of measurement: Activated Clotting Time assessment with Coagulometer device according to second.;Percent of abnormal bleeding. Timepoint: Drainage assessment of the drains and chest tubes 12 hours and 36 hours after the end of surgery. Method of measurement: Drainage assessment of the drains and chest tubes according to cubic centimeter.
- Secondary Outcome Measures
Name Time Method